Facile repurposing of peptide–MHC-restricted antibodies for cancer immunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-1696
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Facile repurposing of peptide–MHC-restricted antibodies for cancer immunotherapy ; day:2 ; month:1 ; year:2023 ; pages:1-12
Nature biotechnology ; (2.1.2023), 1-12
- Urheber
-
Yang, Xinbo
Nishimiya, Daisuke
Löchte, Sara
Jude, Kevin M.
Borowska, Marta
Savvides, Christina S.
Dougan, Michael
Su, Leon
Zhao, Xiang
Piehler, Jacob
Garcia, K. Christopher
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41587-022-01567-w
- URN
-
urn:nbn:de:101:1-2023022121183710094093
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yang, Xinbo
- Nishimiya, Daisuke
- Löchte, Sara
- Jude, Kevin M.
- Borowska, Marta
- Savvides, Christina S.
- Dougan, Michael
- Su, Leon
- Zhao, Xiang
- Piehler, Jacob
- Garcia, K. Christopher
- SpringerLink (Online service)
Ähnliche Objekte (12)
Repurposing the yellow fever vaccine for intratumoral immunotherapy
Development of MHC-dependent immunotherapy for gliomas
Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer
Computational immunology : from MHC-peptide binding to immunotherapy
Facile synthetic entry into rotationally restricted 9-arylacridines
Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy
Combination immunotherapy overcomes resistance in MHC class I-deficient cancer
The chaperones p97 and BAG6 in MHC class I-restricted antigen processing
T cell response to an MHC-II restricted epitope of rodent malaria
Computational Methods to Find and Rank MHC-I Restricted Tumor-Associated Antigens to Improve Therapeutic Efficacy and Tolerability of Antigen-based Cancer Immunotherapy
Drug repurposing
MHC-I genotype and tumor mutational burden predict response to immunotherapy
Repurposing the yellow fever vaccine for intratumoral immunotherapy
Development of MHC-dependent immunotherapy for gliomas
Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer
Computational immunology : from MHC-peptide binding to immunotherapy
Facile synthetic entry into rotationally restricted 9-arylacridines
Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy
Combination immunotherapy overcomes resistance in MHC class I-deficient cancer
The chaperones p97 and BAG6 in MHC class I-restricted antigen processing
T cell response to an MHC-II restricted epitope of rodent malaria
Computational Methods to Find and Rank MHC-I Restricted Tumor-Associated Antigens to Improve Therapeutic Efficacy and Tolerability of Antigen-based Cancer Immunotherapy
Drug repurposing
MHC-I genotype and tumor mutational burden predict response to immunotherapy
Repurposing the yellow fever vaccine for intratumoral immunotherapy
Development of MHC-dependent immunotherapy for gliomas
Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer
Computational immunology : from MHC-peptide binding to immunotherapy
Facile synthetic entry into rotationally restricted 9-arylacridines
Enhanced presentation of MHC class Ia, Ib and class II-restricted peptides encapsulated in biodegradable nanoparticles: a promising strategy for tumor immunotherapy
Combination immunotherapy overcomes resistance in MHC class I-deficient cancer
The chaperones p97 and BAG6 in MHC class I-restricted antigen processing
T cell response to an MHC-II restricted epitope of rodent malaria
Computational Methods to Find and Rank MHC-I Restricted Tumor-Associated Antigens to Improve Therapeutic Efficacy and Tolerability of Antigen-based Cancer Immunotherapy
Drug repurposing